Ruggedness of Visible-Residue Limits for Cleaning (Part II) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ruggedness of Visible-Residue Limits for Cleaning (Part II)
The author challenges current detection methodologies.


Pharmaceutical Technology
Volume 35, Issue 3, pp. 122-128

Conclusion

The presentation order of the coupons appears to have no effect on the determination of VRLs. Both a sequential presentation from high to low concentration and a random presentation resulted in the same conclusions for VRL levels, thus confirming the ruggedness of the VRL determination.

Richard Forsyth is a senior consultant with Hyde Engineering + Consulting, 6260 Lookout Rd., Suite 120, Boulder, CO 80301, tel. 303.530.4526, fax 303.581.0839,
.

Submitted: Oct. 1, 2010. Accepted: Dec. 1, 2010.

References

1. R.J. Forsyth and V. Van Nostrand, Pharm. Technol. 28 (10), 58–72 (2004).

2. R.J. Forsyth and V. Van Nostrand, Pharm. Technol. 29 (10), 152–161 (2005).

3. R.J. Forsyth and V. Van Nostrand, Pharm. Technol. 29 (4), 134–140 (2005).

4. R.J. Forsyth, J.L. Hartman, and V. Van Nostrand, Pharm. Technol. 31 (4), 134–140 (2007).

5. R.J. Forsyth et al., Pharm. Technol. 30 (11), 90–100 (2006).

6. R.J. Forsyth, Pharm. Technol. 33 (3), 102–111 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here